BCP-T.A.

BCP-T.A. is a ferroptosis inducer. It induces ferroptosis in NCI H522 non-small cell lung cancer (NSCLC) cells (IC50 = 17 nM), an effect that can be blocked by the ferroptosis inhibitor liproxstatin-1 (Cay-17730). BCP-T.A. binds to glutathione peroxidase (GPX4) and increases the accumulation of lipid peroxides in NCI H522 cells when used at a concentration of 0.5 µM. It is cytotoxic to WI38 human lung fibroblasts and mouse embryonic fibroblasts (MEFs, IC50s = 22 and 10 nM, respectively), as well as NCI H522, HT-1080 fibrosarcoma, MDA-MB-468 and MDA-MB-231 breast, and HeLa cervical cancer cells (IC50s = 17, 19, 84, 21, and 242 nM, respectively).Formal Name: [4-[bis(4-chlorophenyl)methyl]-1-piperazinyl](2-ethynyl-4-thiazolyl)-methanone. CAS Number: 2786829-70-5. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: 3 mg/ml, DMSO: 10 mg/ml, Ethanol: 12 mg/ml. SMILES: O=C(N1CCN(C(C2=CC=C(C=C2)Cl)C3=CC=C(C=C3)Cl)CC1)C4=CSC(C#C)=N4. InChi Code: InChI=1S/C23H19Cl2N3OS/c1-2-21-26-20(15-30-21)23(29)28-13-11-27(12-14-28)22(16-3-7-18(24)8-4-16)17-5-9-19(25)10-6-17/h1,3-10,15,22H,11-14H2. InChi Key: XWHYWEHRTWXUFV-UHFFFAOYSA-N.